17,000 English patients are surviving Stage 4 cancer for two years or more, new data shows

pharmafile | November 8, 2017 | News story | Research and Development Cancer, bladder cancer, breast cancer, colon cancer, lung cancer, pharma, prostate cancer 

At least 17,000 people in the UK are living with Stage 4 cancer and have survived for two years or more, according to new data revealed by Macmillan Cancer Support and Public Health England’s (PHE) National Cancer Registration and Analysis Service.

Presented this week at the 2017 National Cancer Research Institute Conference in Liverpool, the previously unavailable figures are derived from England’s national cancer registry, gathering data on patients diagnosed with the top ten most common cancers between 2012 and 2013 who are still alive by the end of 2015.

These cancers included: bladder; female breast; colorectal; kidney, renal pelvis and ureter; lung, trachea and bronchus; melanoma of skin; non-Hodgkin’s lymphoma; ovary; prostate and uterine cancer. The total figure of 17,000 itself includes 1,200 cases of Stage 4 lung cancer, 2,300 cases of Stage 4 bowel cancer, and 1,600 women with Stage 4 breast cancer and 6,400 men with Stage 4 prostate cancer.

“Advances in treatment and care mean that a growing number of people have cancer that cannot be cured, but can be managed by treatments that alleviate the symptoms and may also prolong their life,” explained Adrienne Betteley, Macmillan Cancer Support’s Specialist Adviser for end-of-life care. “This is really positive news, but living with advanced cancer can be a difficult situation to be in. As well as dealing with the physical symptoms of cancer and having multiple hospital appointments, scans and treatment options to contend with, there’s also the emotional and psychological impact of having an uncertain future.”

Matt Fellows

Related Content

FDA approves AstraZeneca’s Truqap plus Faslodex for breast cancer treatment

AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Truqap (capivasertib) …

FDA approves BMS’s Augtyro for lung cancer treatment

Bristol Myers Squibb has announced that the US Food and Drug Administration (FDA) has approved …


First patient dosed in AdvanCell’s phase 1/2 trial for prostate cancer treatment

AdvanCell has announced that the first patient has been dosed with 212Pb-ADVC001 in its phase …

Latest content